ArticleEmerging infectious diseases2026
Evaluation of Effectiveness of Autocidal Gravid Ovitraps for Preventing Zika Virus Infection, Puerto Rico, USA.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI-Driven Approaches for the Detection, Classification, and Surveillance of Viral Pathogens: Current Advances, Challenges, and Future Directions.Pathogens (Basel, Switzerland) · 2026Review
- Strategies for controllingCaribbean journal of science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aedes aegypti mosquitoes drive arboviral outbreaks in tropical regions. Zika virus (ZIKV), linked to congenital and neurologic complications, caused a major outbreak in Puerto Rico, USA, in 2016, infecting ≈26% of the population. Autocidal gravid ovitraps (AGOs), pesticide-free devices targeting gravid Ae. aegypti mosquitoes, have been shown to reduce transmission of another arbovirus, chikungunya. During March-May 2017, we conducted a household-based serosurvey in 4 demographically similar communities in southeastern Puerto Rico, 2 with long-term AGO deployment (≈85% coverage) and 2 without, to assess effects of AGOs on ZIKV transmission. Among 271 participants >5 years of age, ZIKV seroprevalence was much lower in intervention than nonintervention communities (9.6% vs. 20.0%). Protective effects were strongest among older adults, larger households (>4 persons), and persons spending more time at home. Although study design and measurement limitations could limit generalizability of results, our findings support AGOs as sustainable nonchemical tools for reducing ZIKV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.